MedKoo Cat#: 578048 | Name: Nebentan potassium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nebentan potassium is a substituted phenylethenesulfonamide and selective endothelin A receptor antagonist. Nebentan potassium inhibits endothelin-mediated mechanisms involved in tumor cell growth and progression, angiogenesis, and metastasis.

Chemical Structure

Nebentan potassium
Nebentan potassium
CAS#342005-82-7

Theoretical Analysis

MedKoo Cat#: 578048

Name: Nebentan potassium

CAS#: 342005-82-7

Chemical Formula: C24H20KN5O5S

Exact Mass: 529.0822

Molecular Weight: 529.61

Elemental Analysis: C, 54.43; H, 3.81; K, 7.38; N, 13.22; O, 15.10; S, 6.05

Price and Availability

Size Price Availability Quantity
5mg USD 435.00 2 Weeks
10mg USD 700.00 2 Weeks
25mg USD 1,150.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Nebentan potassium; YM-598 potassium; YM 598 potassium; YM598 potassium
IUPAC/Chemical Name
potassium (E)-(6-methoxy-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)(styrylsulfonyl)amide
InChi Key
WOPWEXSDEXIRNG-ZUQRMPMESA-N
InChi Code
InChI=1S/C24H20N5O5S.K/c1-32-18-11-6-7-12-19(18)34-20-21(29-35(30,31)16-13-17-9-4-3-5-10-17)27-23(28-24(20)33-2)22-25-14-8-15-26-22;/h3-16H,1-2H3;/q-1;+1/b16-13+;
SMILES Code
[K+].COc1ccccc1Oc2c([N-]S(=O)(=O)\C=C\c3ccccc3)nc(nc2OC)c4ncccn4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 529.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ukai M, Yuyama H, Fujimori A, Koakutsu A, Sanagi M, Ohtake A, Sato S, Sudoh K, Sasamata M, Miyata K. In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract. Eur J Pharmacol. 2008 Feb 12;580(3):394-400. Epub 2007 Nov 23. PubMed PMID: 18078923. 2: Someya A, Yuyama H, Fujimori A, Ukai M, Fukushima S, Sasamata M. Effect of YM598, a selective endothelin ETA receptor antagonist, on endothelin-1-induced bone formation. Eur J Pharmacol. 2006 Aug 14;543(1-3):14-20. Epub 2006 Jun 27. PubMed PMID: 16843458. 3: Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Noguchi Y, Sudoh K, Sasamata M, Miyata K. A novel and selective endothelin ET(A) receptor antagonist YM598 prevents the development of chronic hypoxia-induced pulmonary hypertension in rats. Vascul Pharmacol. 2005 Jun;43(1):40-6. Epub 2005 Apr 21. PubMed PMID: 15975532. 4: Yuyama H, Koakutsu A, Fujiyasu N, Fujimori A, Sato S, Shibasaki K, Tanaka S, Sudoh K, Sasamata M, Miyata K. Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S479-82. PubMed PMID: 15838353. 5: Sugimoto K, Fujimori A, Yuyama H, Tahara A, Fujimura A. Renal protective effect of YM598, a selective endothelin type A receptor antagonist. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S451-4. PubMed PMID: 15838346. 6: Sudoh K, Yuyama H, Noguchi Y, Fujimori A, Ukai M, Ohtake A, Sato S, Sasamata M, Miyata K. Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S390-3. PubMed PMID: 15838329. 7: Fujimori A, Miyauchi T, Sakai S, Yuyama H, Iemitsu M, Sanagi M, Sudoh K, Goto K, Shikama H, Yamaguchi I. YM598, an orally active ET(A) receptor antagonist, ameliorates the progression of cardiopulmonary changes and both-side heart failure in rats with cor pulmonale and myocardial infarction. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S354-7. PubMed PMID: 15838319. 8: Yuyama H, Noguchi Y, Fujimori A, Ukai M, Fujiyasu N, Ohtake A, Sato S, Sudoh K, Sasamata M, Miyata K. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. Eur J Pharmacol. 2004 Sep 13;498(1-3):171-7. PubMed PMID: 15363992. 9: Yuyama H, Fujimori A, Sanagi M, Koakutsu A, Sudoh K, Sasamata M, Miyata K. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Eur J Pharmacol. 2004 Aug 2;496(1-3):129-39. PubMed PMID: 15288584. 10: Yuyama H, Sonoda R, Shibasaki K, Fujimori A, Sudoh K, Sasamata M, Miyata K. Effect of single oral administration of YM598, a novel selective endothelin ETA receptor antagonist, on blood pressure in normotensive and hypertensive rats. Vascul Pharmacol. 2004 Feb;41(1):27-34. PubMed PMID: 15135329.